Cargando…
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report
For approval, a proposed generic drug product must demonstrate it is bioequivalent (BE) to the reference listed drug product. For locally acting drug products, conventional BE approaches may not be feasible because measurements in local tissues at the sites of action are often impractical, unethical...
Autores principales: | Tan, Ming‐Liang, Chandran, Sajeev, Jereb, Rebeka, Alam, Khondoker, Bies, Robert, Kozak, Darby, Walenga, Ross, Le Merdy, Maxime, Babiskin, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196416/ https://www.ncbi.nlm.nih.gov/pubmed/36851886 http://dx.doi.org/10.1002/psp4.12952 |
Ejemplares similares
-
Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation
por: Le Merdy, Maxime, et al.
Publicado: (2022) -
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report
por: Walenga, Ross L., et al.
Publicado: (2022) -
In Silico Methods for Development of Generic Drug–Device Combination Orally Inhaled Drug Products
por: Walenga, Ross L., et al.
Publicado: (2019) -
Mechanistic modeling of drug products applied to the skin: A workshop summary report
por: Tsakalozou, Eleftheria, et al.
Publicado: (2022) -
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview
por: Babiskin, Andrew, et al.
Publicado: (2023)